Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
70 participants
INTERVENTIONAL
2015-06-30
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BRTO
Balloon-occluded retrograde transvenous obliteration
Balloon-occluded retrograde transvenous obliteration
Balloon-occluded retrograde transvenous obliteration
Lauromacrogol
NBCA
Endoscopic cyanoacrylate injection
Endoscopic cyanoacrylate injection
Endoscopic cyanoacrylate injection
N-butyl-2-cyanoacrylate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Balloon-occluded retrograde transvenous obliteration
Balloon-occluded retrograde transvenous obliteration
Endoscopic cyanoacrylate injection
Endoscopic cyanoacrylate injection
N-butyl-2-cyanoacrylate
Lauromacrogol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with high risk gastric varices (GOV2 or IGV1)
3. Presence of gastrorenal shunt
Exclusion Criteria
2. Previous treatment of gastric varices.
3. Non-cirrhotic portal hypertension
4. Contraindications to cyanoacrylate injection or BRTO
5. Portal cavernoma
6. Hepatorenal syndrome
7. Proven malignancy including hepatocellular carcinoma
8. End-stage renal disease under renal replacement therapy;
9. Cardiorespiratory failure
10. Pregnancy or patients not giving informed consent for endoscopic procedures
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
luo xuefeng
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xuefeng Luo, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRTO-NBCA-PP
Identifier Type: -
Identifier Source: org_study_id